Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus CHLORTHALIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus CHLORTHALIDONE.
ATACAND HCT vs CHLORTHALIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Thiazide-like diuretic; inhibits sodium-chloride cotransporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Also lowers peripheral vascular resistance.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Oral: 25-100 mg once daily; initial dose 25 mg once daily; may increase to 50-100 mg once daily based on response.
None Documented
None Documented
Clinical Note
moderateChlorthalidone + Digoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin."
Clinical Note
moderateChlorthalidone + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin."
Clinical Note
moderateChlorthalidone + Deslanoside
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside."
Clinical Note
moderateCandesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal half-life 40-60 hours (range 35-70h); prolonged in renal impairment
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal: 50-65% unchanged; biliary/fecal: minimal (<5%)
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic
Chlorthalidone + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin."